Navigation Links
Thomson Reuters Research Forecasts the Onset of the Targeted Drug Discovery Era
Date:12/22/2011

PHILADELPHIA and LONDON, Dec. 22, 2011 /PRNewswire/ -- In recognition of the International Year of Chemistry 2011, Thomson Reuters published a research report analyzing The Changing Role of Chemistry in Drug Discovery. By tracking pharmaceutical industry data over the last decade along with insights from industry experts, the new report forecasts the end of the blockbuster drug era. In its place, the report suggests, a much more targeted, patient-specific approach will define the next decade for the pharmaceutical industry and the patients it serves.

(Photo:  http://photos.prnewswire.com/prnh/20111222/NY26822 )

Leveraging data and analytics from the Thomson Reuters Integrity drug discovery database, the report analyzes pharmaceutical industry productivity, patent data, changing dynamics in the new drug pipeline and trends in the use of biomarkers, among several other factors. Following are some of the key findings in the new report:

  • Improved Strategies for Development: Sales of pharmaceutical products have increased almost two and a half times since 2000, yet it is taking approximately 20 percent longer to get new drugs to market. To remain competitive, major pharmas are utilizing innovative new development strategies to improve output.
  • Repurposed Drugs Create New Opportunities: The high cost of drug discovery has led companies to repurpose existing drugs for rare diseases, increasing their return on investment and driving overall development costs down, while also addressing the needs of individuals suffering from these "rare" illnesses. Repurposed drugs have grown from approximately 80 in 2001 to 222 by 2010, a 300 percent increase.
  • Growing Role of Biopharmaceuticals: While new chemical entities are still the main focus of pharmaceutical research, the number of biopharmaceuticals entering Phase I clinical trials has risen each year since 2001.
  • Biomarker Use Accelerates: Over the last three years, the use of biomarkers related to drug development has increased dramatically, indicating an increased industry focus on specialized patient selection and personalized medicine.
  • Patenting in China, India and Korea on the Rise: Emerging markets such as China, India and Korea are growing in significance for pharmaceutical companies with their growing consumer class and emphasis on innovation. Patent data shows drug discovery in these regions increasing steadily over the last five years, in contrast to the pharmaceutical patent activity in North America, Europe and Japan.

"This report suggests a fundamental change in the drug discovery process, opening up new ways of working and collaborating for companies, nations and academia alike," said Jon Brett-Harris, executive vice president of the Life Sciences business of Thomson Reuters. "The pharmaceutical industry has evolved over the months and years leading up to 2011, the International Year of Chemistry, and Thomson Reuters offers a number of solutions to help address additional challenges in key areas such as benchmarking, competitive intelligence, research, and clinical trials."

The full research findings are available in the new report, The Changing Role of Chemistry in Drug Discovery. Data from the report was drawn from Thomson Reuters Integrity, a unique knowledge solution that integrates biology, chemistry and pharmacology data on more than 320,000 compounds with demonstrated biological activity and almost 140,000 patent family records. Integrity provides researchers with reliable, detailed information across multiple disciplines and from the perspective of a scientist – to support successful drug research and development.

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 55,000 people and operates in over 100 countries. Thomson Reuters shares are listed on the Toronto and New York Stock Exchanges. For more information, go to www.thomsonreuters.com.


'/>"/>
SOURCE Thomson Reuters
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. The National Cancer Institute Joins the Global Community of Scientists Now Using BIOMARKERcenter From Thomson Reuters
2. Despite Decline in Share of Global Output, U.S. Science Impact Still Strong, Says Thomson Reuters
3. Thomson Reuters Names Hottest Researchers and Papers of 2007-2008
4. APS Healthcare and Thomson Reuters to Manage New York States Medicaid Clinical Best Practices Review Program
5. Thomson Reuters Commemorates World IP Week with Series of Strategic Intellectual Property Seminars Across the U.S.
6. Thomson Reuters Examines Highly Cited Research in Bioterrorism
7. Thomson Reuters Makes Disease Briefing on Influenza Covering H1N1 (Swine Flu) Publicly Available
8. Brazils Scientific Research On The Rise, Thomson Reuters Study Finds
9. Thomson Reuters Partners With Sagient Research
10. Thomson Reuters Announces 2009 Edition of the CMR International Pharmaceutical R&D Factbook
11. Thomson Reuters Joins the InChI Trust
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)...   ViaCyte, Inc ., a leading, privately-held ... cell-derived islet replacement therapy for the treatment of ... that ViaCyte and Janssen Biotech, Inc., one of ... have agreed to consolidate the assets of the ... ViaCyte with an exclusive license to all BetaLogics ...
(Date:2/3/2016)... BRUNSWICK, N.J. , Feb. 3, 2016 /PRNewswire-USNewswire/ ... grants totaling more than $1 million for researchers ... are working on health-related research that demonstrates exciting ... this round of funding for the New Jersey ... for faculty members at these educational institutions— Princeton ...
(Date:2/3/2016)... MEDFORD, Mass. , Feb. 3, 2016  Silk Therapeutics, ... A2 financing round. Silk Therapeutics has now raised a total ... progress made by the company. The Series A2 round was ... Foxboro, Massachusetts , with participation from new investors Lear ... Sheri and Roy P. Disney ; Richard Sackler ...
(Date:2/3/2016)... ... February 03, 2016 , ... Big games come and go, but ... much for our country. CereScan, a nationally recognized brain diagnostics and technology company, will ... Football Team (WWAFT) vs. NFL Stars Flag Football Game on February 6, 2016. ...
Breaking Biology Technology:
(Date:1/8/2016)... MANCHESTER, United Kingdom , Jan. 8, 2016 ... innovative sensor-based diagnostic products, today announced the closing of a ... existing investors.  Proceeds from the financing will be used to ... hand-held device for detecting early-stage pressure ulcers. ... after receiving CE Mark approval. The device,s introduction has ...
(Date:1/7/2016)... , Jan. 7, 2016 This BCC Research ... for biometric technologies and devices, identifying newer markets and ... various types of biometric devices. Includes forecast from 2015 ... Identify newer markets and explore the expansion of the ... Examine each type of biometric technology, determine its current ...
(Date:1/7/2016)... -- A United States District Court in Illinois ... to interpret a biometric privacy statute in a decision ... photo website Shutterfly brought by the law firm Carey Rodriguez ... SHUTTERFLY, INC.; and THISLIFE, INC ( N.D. Ill ., ... Illinois Biometric Privacy Act by collecting and scanning face ...
Breaking Biology News(10 mins):